|
Ark Therapeutics Group Plc - Comparative Business Analysis Snapshot
Business Description
Ark Therapeutics Group Plc. The Group's principal activity is discovering, developing and commercialising products in areas of specialist medicine with particular focus on vascular disease and cancer. Its pharmaceutical business focuses on gene-based medicine that harnesses healthy brain cells to destroy cancer cells that attempt to proliferate. It is used for the treatment of patients with operable high-grade glioma, where the average survival period for patients, once diagnosed, is about eight months. It also has products designed to prevent the blocking of veins after vascular surgery. Product brands are Cerepro, Vitor and Trinam. In addition, the Group also has wound care portfolio centered on the prevention and treatment of foot, lower-leg and infected wounds. Its product brands include Kerrabot, Kerraped, Neuropad and Flaminal. The Group operates in the United Kingdom and Finland.
Competitor Analysis
This analysis compares Ark Therapeutics Group Plc with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
